BR9811037A - Utilização de ligantes mhc classe ii como coadjuvante para vacinação e de lag-3 no tratamento do câncer - Google Patents
Utilização de ligantes mhc classe ii como coadjuvante para vacinação e de lag-3 no tratamento do câncerInfo
- Publication number
- BR9811037A BR9811037A BR9811037-3A BR9811037A BR9811037A BR 9811037 A BR9811037 A BR 9811037A BR 9811037 A BR9811037 A BR 9811037A BR 9811037 A BR9811037 A BR 9811037A
- Authority
- BR
- Brazil
- Prior art keywords
- lag
- vaccination
- mhc class
- class
- ligands
- Prior art date
Links
- 239000003446 ligand Substances 0.000 title abstract 4
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 201000011510 cancer Diseases 0.000 title abstract 3
- 238000002255 vaccination Methods 0.000 title abstract 2
- 101100510617 Caenorhabditis elegans sel-8 gene Proteins 0.000 title 1
- 239000002671 adjuvant Substances 0.000 title 1
- 102000017578 LAG3 Human genes 0.000 abstract 3
- 101150030213 Lag3 gene Proteins 0.000 abstract 3
- 239000000427 antigen Substances 0.000 abstract 3
- 102000036639 antigens Human genes 0.000 abstract 3
- 108091007433 antigens Proteins 0.000 abstract 3
- 230000028993 immune response Effects 0.000 abstract 2
- 102000043131 MHC class II family Human genes 0.000 abstract 1
- 108091054438 MHC class II family Proteins 0.000 abstract 1
- 239000011230 binding agent Substances 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 238000009169 immunotherapy Methods 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP97401800A EP0893507A1 (en) | 1997-07-25 | 1997-07-25 | Use of MHC class II ligands (CD4 and LAG-3) as adjuvant for vaccination and of LAG-3 in cancer treatment |
PCT/EP1998/004621 WO1999004810A2 (en) | 1997-07-25 | 1998-07-23 | Use of mhc class ii ligands as adjuvant for vaccination and of lag-3 in cancer treatment |
Publications (1)
Publication Number | Publication Date |
---|---|
BR9811037A true BR9811037A (pt) | 2000-08-01 |
Family
ID=8229825
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR9811037-3A BR9811037A (pt) | 1997-07-25 | 1998-07-23 | Utilização de ligantes mhc classe ii como coadjuvante para vacinação e de lag-3 no tratamento do câncer |
Country Status (20)
Country | Link |
---|---|
US (2) | US6410509B1 (pt) |
EP (3) | EP0893507A1 (pt) |
JP (1) | JP4723722B2 (pt) |
KR (1) | KR100603075B1 (pt) |
CN (1) | CN1184320C (pt) |
AT (2) | ATE324455T1 (pt) |
AU (1) | AU753738B2 (pt) |
BR (1) | BR9811037A (pt) |
CA (2) | CA2293805C (pt) |
DE (2) | DE69834330T2 (pt) |
DK (1) | DK1002108T3 (pt) |
EA (3) | EA003740B1 (pt) |
EE (1) | EE200000039A (pt) |
ES (1) | ES2262242T3 (pt) |
HK (1) | HK1030014A1 (pt) |
IL (2) | IL134212A0 (pt) |
NO (1) | NO20000378D0 (pt) |
PT (1) | PT1002108E (pt) |
UA (1) | UA75322C2 (pt) |
WO (1) | WO1999004810A2 (pt) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE519779T1 (de) * | 2001-09-19 | 2011-08-15 | Roussy Inst Gustave | An das glu-pro motiv-bindende proteine und peptide, diese enthaltende therapeutische zusammensetzungen und deren anwendungen |
AU2004217526B2 (en) * | 2003-02-28 | 2010-02-04 | St. Jude Children's Research Hospital Inc. | T cell regulation |
KR20050082389A (ko) * | 2004-02-18 | 2005-08-23 | 메덱스젠 주식회사 | 직렬 연쇄체를 갖는 면역접합체를 포함하는 장기이식합병증 치료용 약제학적 조성물 |
FR2868781B1 (fr) | 2004-04-13 | 2008-02-22 | Immutep | Composition de vaccin comprenant un ligand cmh de classe ii couple a un antigene, procede de preparation et utilisations |
EP2044949A1 (en) * | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
WO2011031139A1 (en) | 2009-09-09 | 2011-03-17 | Universiteit Utrecht Holding B.V. | An ataq protein or a part thereof as a vaccine |
SA110310855B1 (ar) | 2009-11-13 | 2014-09-16 | Laboratories Leti S L Unipersonal | استخدام مصدر l3 و/ أو l5 كلقاح أو كوسيلة تشخيصية لمرض طفيلي |
AR083829A1 (es) | 2010-11-10 | 2013-03-27 | Leti S L Unipersonal Lab | Coadyuvante con potencialidad inmunogenica incrementada |
GB201322626D0 (en) | 2013-12-19 | 2014-02-05 | Immutep S A | Combined preparations for the treatment of cancer |
JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
CN103751778B (zh) * | 2014-01-28 | 2016-09-28 | 复旦大学 | 3′-脱氧腺苷在制备广谱疫苗增效的免疫佐剂中的应用 |
US20150259420A1 (en) | 2014-03-14 | 2015-09-17 | Novartis Ag | Antibody molecules to lag-3 and uses thereof |
CN107001418A (zh) | 2014-10-07 | 2017-08-01 | Cytlimic公司 | 源于hsp70的肽、使用其的用于治疗或预防癌症的医药组合物、免疫诱导剂、及抗原呈递细胞的制造方法 |
US9827308B2 (en) | 2014-12-10 | 2017-11-28 | Wisconsin Alumni Research Foundation | Mini-intronic plasmid DNA vaccines in combination with LAG3 blockade |
GB201500374D0 (en) | 2015-01-09 | 2015-02-25 | Immutep S A | Combined preparations for the treatment of cancer |
DK3269733T3 (da) | 2015-03-09 | 2020-07-27 | Cytlimic Inc | Peptid afledt af gpc3, farmaceutisk sammensætning til behandling eller forebyggelse af cancer under anvendelse deraf, immunitetsinducer og fremgangsmåde til fremstilling af antigenpræsenterende celler |
JP6311094B2 (ja) * | 2015-04-07 | 2018-04-18 | サイトリミック株式会社 | 医薬 |
EP3294324A1 (en) | 2015-05-13 | 2018-03-21 | Agenus Inc. | Vaccines for treatment and prevention of cancer |
MX2017016844A (es) | 2015-07-16 | 2018-08-15 | Biokine Therapeutics Ltd | Composiciones y procedimientos para tratar cancer. |
US10265379B2 (en) | 2015-09-16 | 2019-04-23 | Annabelle Rodriguez Oquendo | Use of recombinant lymphocyte activation gene-3 as a companion therapeutic for patients at risk for cardiovascular disease and other chronic inflammatory diseases |
US20180256633A1 (en) | 2015-09-18 | 2018-09-13 | Rijksuniversiteit Groningen | Long chain inulin for stimulating an immune response |
TW201813664A (zh) | 2016-10-11 | 2018-04-16 | 賽多利克公司 | 醫藥 |
CN108204958A (zh) * | 2016-12-19 | 2018-06-26 | 伊缪泰普有限公司 | 结合测定 |
EP3784688A2 (en) | 2018-04-26 | 2021-03-03 | Agenus Inc. | Heat shock protein-binding peptide compositions and methods of use thereof |
BR112021005221A2 (pt) * | 2018-09-27 | 2021-06-15 | Genocea Biosciences Inc. | métodos de tratamento |
JP2020138940A (ja) | 2019-02-28 | 2020-09-03 | テルモ株式会社 | 治療方法 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT88641B (pt) * | 1987-10-02 | 1993-04-30 | Genentech Inc | Metodo para a preparacao de uma variante de adesao |
JPH03505039A (ja) * | 1988-08-22 | 1991-11-07 | アメリカ合衆国 | 可溶性cd4を発現するレトロウイルスベクター、エイズの遺伝子治療法 |
JPH02231083A (ja) * | 1988-08-31 | 1990-09-13 | Eisai Co Ltd | 組換ナチュラルキラー細胞活性化因子 |
EP0385909B1 (en) * | 1989-03-03 | 1994-07-13 | MicroGeneSys, Inc. | A kit or composition for the prevention or treatment of HIV-1 infections |
EP0394827A1 (en) * | 1989-04-26 | 1990-10-31 | F. Hoffmann-La Roche Ag | Chimaeric CD4-immunoglobulin polypeptides |
FR2656800B1 (fr) * | 1990-01-08 | 1992-05-15 | Roussy Inst Gustave | Nouvelles proteines produits par les lymphocytes humains, sequence d'adn codant pour ces proteines et applications pharmaceutiques et biologiques. |
US5851828A (en) * | 1991-03-07 | 1998-12-22 | The General Hospital Corporation | Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells |
ES2249760T3 (es) * | 1993-01-26 | 2006-04-01 | The Trustees Of The University Of Pennsylvania (A Corporation Of Pennsylvania) | Composiciones y procedimientos de administracion de materias geneticas. |
SE510135C2 (sv) * | 1994-05-05 | 1999-04-19 | Berol Nobel Ab | Vattenhaltig suspension av en cellulosaeter, sätt för dess framställning samt komposition |
ATE352617T1 (de) * | 1994-05-06 | 2007-02-15 | Roussy Inst Gustave | Lösliche polypeptidfraktionen des lag-3-proteins; verfahren zur herstellung; therapeutische zusamensetzung; antiidiotypischer antikörper |
MX9700560A (es) * | 1994-08-05 | 1997-05-31 | Warner Lambert Co | Metodo de uso de integrasa retroviral negativa transdominante en el tratamiento de infecciones retrovirales. |
JP2001506122A (ja) * | 1994-12-07 | 2001-05-15 | エフ.ホフマン−ラ ロシュ アーゲー | 免疫抑制作用を有するモノクローナル抗体断片 |
CN1171117A (zh) * | 1994-12-23 | 1998-01-21 | 实验室奥姆公司 | Mhc-ⅱ结合和/或mhc-ⅱ模拟分子用于预防和/或治疗炎性疾病的用途 |
DE69627527T2 (de) * | 1995-12-28 | 2004-03-04 | The Johns Hopkins University School Of Medicine | Allogene parakrine cytokine tumor impfstoffe |
-
1997
- 1997-07-25 EP EP97401800A patent/EP0893507A1/en not_active Withdrawn
-
1998
- 1998-07-23 AT AT98945090T patent/ATE324455T1/de active
- 1998-07-23 IL IL13421298A patent/IL134212A0/xx unknown
- 1998-07-23 EE EEP200000039A patent/EE200000039A/xx unknown
- 1998-07-23 ES ES98945090T patent/ES2262242T3/es not_active Expired - Lifetime
- 1998-07-23 DK DK98945090T patent/DK1002108T3/da active
- 1998-07-23 DE DE69834330T patent/DE69834330T2/de not_active Expired - Lifetime
- 1998-07-23 CA CA2293805A patent/CA2293805C/en not_active Expired - Lifetime
- 1998-07-23 EA EA200000161A patent/EA003740B1/ru not_active IP Right Cessation
- 1998-07-23 EP EP98945090A patent/EP1002108B1/en not_active Expired - Lifetime
- 1998-07-23 AU AU92547/98A patent/AU753738B2/en not_active Expired
- 1998-07-23 CA CA2732570A patent/CA2732570C/en not_active Expired - Lifetime
- 1998-07-23 WO PCT/EP1998/004621 patent/WO1999004810A2/en active IP Right Grant
- 1998-07-23 JP JP2000503862A patent/JP4723722B2/ja not_active Expired - Lifetime
- 1998-07-23 EA EA200300092A patent/EA200300092A1/ru unknown
- 1998-07-23 AT AT06008545T patent/ATE478956T1/de not_active IP Right Cessation
- 1998-07-23 EP EP06008545A patent/EP1698701B1/en not_active Expired - Lifetime
- 1998-07-23 KR KR1020007000265A patent/KR100603075B1/ko not_active IP Right Cessation
- 1998-07-23 DE DE69841866T patent/DE69841866D1/de not_active Expired - Lifetime
- 1998-07-23 EA EA200200565A patent/EA005405B1/ru not_active IP Right Cessation
- 1998-07-23 UA UA2000020976A patent/UA75322C2/uk unknown
- 1998-07-23 CN CNB988075474A patent/CN1184320C/zh not_active Expired - Lifetime
- 1998-07-23 PT PT98945090T patent/PT1002108E/pt unknown
- 1998-07-23 BR BR9811037-3A patent/BR9811037A/pt not_active IP Right Cessation
-
2000
- 2000-01-24 IL IL134212A patent/IL134212A/en not_active IP Right Cessation
- 2000-01-25 NO NO20000378A patent/NO20000378D0/no not_active Application Discontinuation
- 2000-01-27 US US09/492,113 patent/US6410509B1/en not_active Expired - Lifetime
-
2001
- 2001-01-30 HK HK01100662A patent/HK1030014A1/xx not_active IP Right Cessation
-
2002
- 2002-01-10 US US10/041,600 patent/US7109026B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR9811037A (pt) | Utilização de ligantes mhc classe ii como coadjuvante para vacinação e de lag-3 no tratamento do câncer | |
Carpentier et al. | Oligodeoxynucleotides containing CpG motifs can induce rejection of a neuroblastoma in mice | |
DK1225870T3 (da) | Sammensætning og fremgangsmåde til cancerantigenimmunterapi | |
Lewis | Therapeutic cancer vaccines: using unique antigens | |
MY155218A (en) | Small molecules useful in the treatment of inflammatory disease | |
PT1187629E (pt) | Composicao adjuvante que compreende saponina e um oligonucleotido imunoestimulador | |
ATE106013T1 (de) | Arzneimittelfreisetzungssystem aus glucan und adjuvant. | |
GEP20053658B (en) | Soluble CTLA4 Mutant Molecules and Uses Thereof | |
ATE314095T1 (de) | Virusähnliche partikel zur induktion von autoantikörpern | |
DE69839273D1 (de) | Krebs immuntherapie mit semi-allogenen zellen | |
ES2177638T3 (es) | Uso de mycobacterium para el tratamiento de tumores. | |
ATE249835T1 (de) | Immunoregulator | |
Garaci | Thymosin α1: a historical overview | |
HUP0004780A2 (hu) | Prosztaglandin agonisták felhasználása merevedési rendellenességek vagy impotencia kezelésében | |
DE60027905D1 (de) | Glycokonjugate, glycoaminosäure, deren zwischenprodukte, und ihre verwendung | |
NZ507829A (en) | Vaccine adjuvants for immunotherapy of melanoma | |
MXPA03010261A (es) | Metodos para tratar cancer. | |
BR0109928A (pt) | Uso de um herpes vìrus atenuado, e, método para estimular uma resposta imune em um indivìduo humano ou animal, ou para tratar ou prevenir uma infecção patogênica ou câncer em um indivìduo humano ou animal | |
BR9807332A (pt) | Antìgenos de leishmania para utilização na terapia e diagnóstico de leishmaniose | |
HUP0302629A2 (hu) | Camptotechin és sztilbénszármazékok kombinációját tartalmazó gyógyszerkészítmények rák kezelésére | |
IT1277926B1 (it) | Uso di muteine di citochine naturali come immunogeni per la preparazione di composizioni farmaceutiche per curare o prevenire | |
MY127452A (en) | Vaccines. | |
NL192326B (nl) | Werkwijze voor het bereiden van een geneesmiddel, waarbij een gezuiverd, ontgift endotoxine samen met een drager en eventueel andere toevoegingen in een voor therapeutische toediening geschikte vorm wordt gebracht. | |
Tourani et al. | Subcutaneous (SC) interleukin-2 (IL-2) plus alpha interferon (IFN-α) and 5 fluororacil (5 FU) in out-patients (pts) with metastatic renal cell carcinoma (MRCC). Scapp II trial | |
DE50305753D1 (de) | Verfahren und mittel zur prävention, hemmung und therapie von krebserkrankungen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B25A | Requested transfer of rights approved |
Owner name: INSTITUT GUSTAVE ROUSSY (FR) , LABORATOIRES SERONO Free format text: TRANSFERIDO DE: APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. |
|
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B25D | Requested change of name of applicant approved |
Owner name: INSTITUT GUSTAVE ROUSSY (FR) , MERCK SERONO S.A. ( |
|
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O E 11; ART. 25 DA LPI |
|
B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL. |
|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A (S) 17A ANUIDADE (S) |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2320 DE 23/06/2015. |
|
B08H | Application fees: decision cancelled [chapter 8.8 patent gazette] | ||
B08H | Application fees: decision cancelled [chapter 8.8 patent gazette] |